drugset / Trial / NCT00840216

Clarithromycin 500 mg Extended Release Tablets Under Non-Fasting Conditions.

NCT00840216

Phase 1 Completed 22 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study is to compare the relative bioequivalence of a test clarithromycin extended release formulation to an equivalent oral dose of the commercially available extended release clarithromycin in a test population of 22 adult subjects under fed conditions.

Timeline

Start
2002-08
Primary completion
2002-08
Completion
2002-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Clarithromycin Small molecule 500 mg Oral

Indications

No indication recorded.